Ask AI
ProCE Banner Activity

Long-Acting Antiretroviral Agents for PrEP: Insights From CROI 2026

Conference Coverage
Clinical Thought

The age of long-acting regimens for pre-exposure prophylaxis (PrEP) to prevent HIV has arrived! Learn how new data from CROI 2026 further support PrEP while addressing injection-site reactions and allaying fears of drug resistance.

Released: March 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Daniel R. Kuritzkes, MD: consultant/advisor/speaker: AbbVie, Gilead, GSK, Merck, ViiV; other financial or material support: Janssen.